This Article Abstract Full Text Full Text (PDF) Correction (v39,p1409) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Opie, L. H. Articles by Schall, R. Search for Related Content PubMed PubMed Citation Articles by Opie, L. H. Articles by Schall, R.

Evidence-based evaluation of calcium channel blockers for hypertension

Equality of mortality and cardiovascular risk relative to conventional therapy

Lionel H. Opie, MD, DPhil, DSc, FACC^*,* and Robert Schall, PhD

^* Hatter Institute, Department of Medicine, Cape Heart Center, University of Cape Town Medical School, Cape Town, South Africa
Quintiles ClinData, Bloemfontein, South Africa

View larger version (21K): [in a new window]   Figure 1 Comparison between calcium channel blocker (CCB) based therapy and conventional therapy. For details, see Tables 2 and 3. Note the decrease (p = 0.001) in nonfatal stroke and the increase in nonfatal myocardial infarction (MI) (p = 0.036). CV = cardiovascular.

View larger version (17K): [in a new window]   Figure 2 Comparison between calcium channel blocker (CCB) based therapy and angiotensin-converting enzyme (ACE) inhibitor-based therapy. For details, see Table 4. Note the increase in nonfatal and total myocardial infarction (MI). CV = cardiovascular.